the aid library

LIST OPTIONS

Filter

9321

WHO Prequalification of Diagnostics Programme - Public report (Product:BDFACSCountTM InstrumentSystemwithFACSCountTM ControlKitandBD FACSCountTM CD4ReagentKit(AbsoluteandPercentageCD4+Counts) )

World Health Organization (2016) C_WHO

Product:BDFACSCountTM InstrumentSystemwithFACSCountTM ControlKitandBD FACSCountTM CD4ReagentKit(AbsoluteandPercentageCD4+Counts) Number: PQDx 0133-045-00 0133-045-00 WHO PQDx PR June/2016, version 2.0

Download (1320)

View PDF (1635)

Core Set of Indicators & Indicator Data Sheets for Health and Social Health Protection

Deutsche Gesellschaft fü; r Internationale Zusammenarbeit (GIZ) GmbH ;; KfW (2012)

The Core Set of Indicators and respective Indicator Data Sheets aim to pave the way towards a common understanding, greater consistency and comparability across countries and alignment of results chains of German Development Cooperation in the field of health and social health protection with the in... more

Download (285)

View PDF (258)

Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (‎TTS)‎ following vaccination to prevent coronavirus disease (‎COVID-19)‎: interim guidance, 19 July 2021

World Health Organization WHO (2021) C_WHO

Download (1314)

View PDF (907)

Antibiotic Stewardship - From Principles to Practice / Ebook

British Society for Antimicrobial Chemotherapy BSAC (2019) C2

This book provides significantly expanded content and experience in relation to a broader stewardship context- for example, stewardship in specific populations, different countries as well as the role of different professions in stewardship to political and media engagement. We hope this book has so... more

Download (450)

View PDF (740)

Democratic Republic of Congo: PROFILE OF PRETERM AND LOW BIRTH WEIGHT PREVENTION AND CARE

Every Preemie—SCALE (2017) C2

The information provided here can be used to understand the current situation, increase attention to preterm births in Rwanda and to inform dialogue and action among stakeholders. Data can be used to identify the most important risk factors to target and gaps in care in order to identify and impleme... more

Download (372)

View PDF (319)

Reforms in the Health Sector in Ukraine. Revolutionizing care: Ukraine's sectoral approach to anti-corruption health

Steingrüber, S. World Bank (2022) C2

Following the 2014 Euromaidan Revolution, Ukraine embarked on a national reform program to reduce widespread corruption within government. In the health sector, the government introduced several complementary reforms that aimed to improve the health outcomes of Ukrainian citizens, but designed in su... more

Download (1092)

View PDF (1733)

Nepal Trend Report: Trends in Demographic and Reproductive Health Indicators in Nepal

Nepal Demographic and Health Survey (2006) C1

Further analysis of the 1996, 2001, and 2006 Demographic and Health Surveys Data

Download (534)

View PDF (1055)

Notes for the record: Consultation on Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) for Ebola Virus Disease (EVD)
recommended

World Health Organization WHO (2018) C_WHO

Update 27 Agusut 2018

Download (607)

View PDF (1005)

Validation of elimination of trachoma as a public health problem

World Health Organization WHO (2016) C_WHO

These standard operating procedures are intended to be used when a Member State wishes to request validation of national elimination of trachoma as a public health problem following implementation of the SAFE strategy,1 which comprises: surgery for trachomatous trichiasis, antibiotics to clear infec... more

Download (177)

View PDF (356)

Global update on implementation of preventive chemotherapy against neglected tropical diseases (‎NTDs)‎ in 2023 and status of donated medicines for NTDs in 2024

World Health Organization WHO (2024) C_WHO

760 WEEKLY EPIDEMIOLOGICAL RECORD, NOS. 51/52, 20 DECEMBER 2024, pp.760-769. In French and English

Download (258)

View PDF (302)

Slowing of the HIV Epidemic in Ukraine: Evidence from Case Reporting and Key Population Surveys, 2005–2012

C. R. Vitek; J.-I. Cakalo; Y .V. Kruglov; et al. PLOS One (2014) C2

PLOS ONE | www.plosone.org September 2014 | Volume 9 | Issue 9 | e103657

Download (310)

View PDF (342)

Impacts of tropical cyclones on food security, health and biodiversity

World Health Organisation (WHO) (2023) C_WHO

Food security, human health and wellbeing largely depend on biodiversity. Biodiversity supports agriculture through ecosystem services such as pollination and water purification, and provides access to natural medicines, which are the primary source of health care for 4 billion people worldwide

External Link

Health Care Financing in Ethiopia: Implications on Access to Essential Medicines

Eskender Eshetu Ali (2014) CC

Value in Health Regional Issues 4 C (2014) 37-40

External Link

A comparative analysis of national HIV policies in six African countries with generalized epidemics

K. Church; F. Kiweewa, A.Dasgupta; et al. Bull World Health Organ; PMC (US National Library of Medicine National Institutes of Health) (2015) C2

Bull World Health Organ 2015;93:457–467 | doi: http://dx.doi.org/10.2471/BLT.14.147215

External Link

Building Health System Capacity Through Implementation Research: Experience of INSPIRE—A Multi-country PMTCT Implementation Research Project

M. Newman Owiredu; N. B. Bellareet; C. C. Chakanyuka Musanhu al. J Acquir Immune Defic Syndr; Wolters Kluwer Health (2017) C2

Supplement Article J Acquir Immune Defic Syndr Volume 75, Supplement 2, June 1, 2017 Building Health Systems through Implementation Research Published by Wolters Kluwer Health, Inc.

Download (294)

View PDF (598)

Zoonoses: Blurred Lines of Emergent Disease and Ecosystem Health - UNEP Frontiers 2016 Report: Emerging Issues of Environmental Concern

United Nations Environment Programme (2016) C2

The 20th century was a period of unprecedented ecological change, with dramatic reductions in natural ecosystems and biodiversity and equally dramatic increases in people and domestic animals. Never before have so many animals been kept by so many people—and never before have so many opportunities... more

External Link

Chinese development assistance and household welfare in sub-Saharan Africa

Bruno Martorano, Laura Metzger, Marco Sanfilippo European University Institute (2019) C1

We combine data on Chinese development projects with data from Demographic and Health Surveys to study the impact of Chinese aid on household welfare in sub-Saharan Africa. We use a novel methodology to test the effect of Chinese aid on three important development outcomes: education, health, and nu... more

Download (543)

View PDF (722)

Polio this week as of 24 July 2019

Global Polio Eradication Initiative (2019) C1

Download (178)

View PDF (442)

The Global Burden of Disease Study at 30 years

Murray, C.J.L. nature medicine (2022) CC

The Global Burden of Disease Study (GBD) began 30 years ago with the goal of providing timely, valid and relevant assessments of critical health outcomes. Over this period, the GBD has become progressively more granular. The latest iteration provides assessments of thousands of outcomes for diseases... more

Download (473)

View PDF (698)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Notes for the record: Consultation on Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) for Ebola Virus Disease (EVD) recommended

Notes for the record: Consultation on Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) for Ebola Virus Disease (EVD)
recommended